Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 5/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 2/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426223 | 0.92 | FAAH (0.46) | FAAHCES2KCNH2CCR5MCHR1 | |
| SCHEMBL428048 | 0.91 | FAAH (0.46) | FAAHCES2KCNH2CCR5MCHR1 | |
| SCHEMBL426166 | 0.88 | FAAH (0.44) | FAAHCES2KCNH2CCR5 | |
| SCHEMBL426140 | 0.86 | DRD2 (0.45) | FAAHCES2KCNH2DRD3CCR5 | |
| SCHEMBL427435 | 0.86 | FAAH (0.42) | FAAHCES2KCNH2CCR5UBE2M | |
| SCHEMBL16430328 | 0.86 | FAAH (0.42) | FAAHCES2KCNH2DRD3CCR5 | |
| SCHEMBL424688 | 0.86 | FAAH (0.58) | FAAHCES2MTOR | |
| SCHEMBL425023 | 0.85 | DRD3 (0.43) | FAAHCES2DRD3CCR5PARP1 | |
| SCHEMBL427174 | 0.85 | FAAH (0.59) | FAAHCES2MTOR | |
| SCHEMBL426209 | 0.85 | FAAH (0.46) | FAAHCES2KCNH2MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885KCNH2 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.